Stirling, UK – STERILE manufacturing expert Symbiosis Pharmaceutical Services has further strengthened its North American presence with the appointment of another experienced U.S. based business development executive. The Scotland-based contract manufacturing organisation (CMO) has engaged Rich Masino to promote its commercial interests on the West Coast of the U.S., which follows the recent appointment of business development manager Derek Richards to oversee its commercial interests on the East Coast. With over 25 years’ experience in the biotech, life science, and pharmaceutical sectors, Rich Masino has specialised in the pharmaceutical contract manufacturing sector over the last decade. Prior to that he has held product development positions at Molecular Devices and Affymetrix and senior commercial roles at Stratagene (Agilent Technologies) and LIFE Technologies (ThermoFisher). He joins Symbiosis to support the CMO’s strategic focus by promoting its core aseptic manufacturing services in North America. Growing demand for these services has been fuelled by increased demand for small scale biologic and small molecule sterile production capabilities to support a growing number of clinical trials globally. Colin MacKay, CEO at Symbiosis Pharmaceutical Services, said: “We continue to raise awareness of our world class capabilities in the North American market in response to increasing demand from biotech and pharma companies seeking service excellence from a regulatory-compliant and time-focused contract sterile fill/finish CMO. “Bringing Rich on board gives us an opportunity to engage directly with new clients located on the West Coast and to support our existing relationships with North American clients. “The challenge ahead is to ensure that companies in the U.S. understand where we can add specific value to their drug development projects. What works in our favour is that we have an outstanding track record of consistently and successfully helping clients achieve their crucial drug development milestones in the most time-efficient way possible.” In just a few years, Symbiosis has built a strong reputation for offering clients rapid access to manufacturing slots and quick release of drug product to ensure tight clinical trial timelines are successfully met. Rich stated: “I have known Colin for many years and have not been surprised by the company’s expansion, which has been lead by the company having a niche focus in terms of providing sterile vial filling services for conventional small molecules, biological, cytotoxic, liquid and lyophilised drug products at a relatively small scale. “I am excited about the firm’s U.S. expansion plans and delighted to be joining the team at this juncture. I’m confident this will be a catalyst for great mutual success in the North American market for many years to come.” Symbiosis specialises in sterile injectables and the aseptic manufacturing of drug products into vials. Its core manufacturing capability takes place within a purpose-built facility in Stirling, Scotland, designed for the manufacture and quick release of sterile drug products at clinical and niche market scale. For further information, images and interview opportunities, please contact Raman Sehgal at ramarketing: [email protected] | 07808796300 | | Twitter: @ramarketingpr | Facebook: /ramarketingpr

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

U.K.-based alpha-synuclein biotech Wren will partner with Japanese pharma Eisai to seek out new ways of targeting neuro disorders.

As Moderna continues to drip-feed the latest data from its late-stage COVID-19 vaccine effort, it has updated the shot’s efficacy figure.

Two research teams have discovered drug combinations that may make it possible to translate CAR-T cell therapies to solid tumors.